Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Restructuring Costs (2024 - 2025)

Corvus Pharmaceuticals has reported Restructuring Costs over the past 2 years, most recently at $561000.0 for Q4 2025.

  • Quarterly results put Restructuring Costs at $561000.0 for Q4 2025, down 28.08% from a year ago — trailing twelve months through Dec 2025 was $3.0 million (down 4.16% YoY), and the annual figure for FY2025 was $3.0 million, down 4.13%.
  • Restructuring Costs for Q4 2025 was $561000.0 at Corvus Pharmaceuticals, down from $617000.0 in the prior quarter.
  • Over the last five years, Restructuring Costs for CRVS hit a ceiling of $994000.0 in Q1 2024 and a floor of $551000.0 in Q2 2024.